| answer text |
<p>The Department is proud to invest £1.3 billion per year into health research, with
more spent on cancer than any other disease group, through the National Institute
for Health and Care Research (NIHR). Department officials meet regularly to discuss
a wide-range of our investments, including into lobular and other breast cancers,
to drive the maximum collective research impact on policy, practice, and individual
lives. The NIHR invests in translational and implementation research to drive innovations
into policy and practice.</p><p>We are proud to have invested £29 million into the
Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research
Centre in 2022, supporting their efforts to strengthen research into cancer, including
lobular breast cancer. This is complemented by wider investments into breast cancer
research including, for example, a £1.3 million project to determine whether an abbreviated
form of breast magnetic resonance imaging can detect breast cancers missed by screening
through mammography, again including lobular breast cancer. Our support to the NIHR’s
Clinical Research Network has enabled the delivery of 10 further lobular breast-cancer
related studies.</p><p>While the NIHR cannot respond to direct solicitations for funding,
instead commissioning on the basis of research excellence, we would welcome more applications
from researchers on lobular breast cancer, including from the ICR. The NIHR funds
research on cancer prevention, detection, diagnosis, and treatment and care, which
saves lives.</p>
|
|
